Clostridium difficile infection: new developments in epidemiology and pathogenesis
The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Abstract
Clostridium difficile is now considered to be one of the most important causes of health care-associated infections. C. difficile infections are also emerging in the community and in animals used for food, and are no longer viewed simply as unpleasant complications that follow antibiotic therapy. Since 2001, the prevalence and severity of C. difficile infection has increased significantly, which has led to increased research interest and the discovery of new virulence factors, and has expanded and focused the development of new treatment and prevention regimens. This Review summarizes the recent epidemiological changes in C. difficile infection, our current knowledge of C. difficile virulence factors and the clinical outcomes of C. difficile infection.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [45]
Citations
Cites
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361 · cited 1×
“It is becoming evident from 16S ribosomal RNA sequencing that disruption of the gut microbiota following antibiotic treatment is much greater than was previously realize”
BackgroundAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006
Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A.-M., Nguyen, T., Frenette, C., Kelly, M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051639 · Cited by 1,946
Interventions to improve antibiotic prescribing practices for hospital inpatients
Davey, P., Brown, E., Charani, E., Fenelon, L., Gould, I. M., Holmes, A., Ramsay, C. R., Wiffen, P. J., & Wilcox, M. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003543.pub3 · Cited by 1,864
Nosocomial Acquisition of Clostridium difficile Infection
McFarland, L. V., Mulligan, M. E., Kwok, R. Y. Y., & Stamm, W. E. (1989) · New England Journal of Medicine · doi:10.1056/nejm198901263200402 · Cited by 1,326
Zar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Glucosylation of Rho proteins by Clostridium difficile toxin B
Just, I., Selzer, J., Wilm, M., Eichel-Streiber, C. V., Mann, M., & Aktories, K. (1995) · Nature · doi:10.1038/375500a0 · Cited by 1,032
Decreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010
Pepin, J., Saheb, N., Coulombe, M.-A., Alary, M.-E., Corriveau, M.-P., Authier, S., Leblanc, M., Rivard, G., Bettez, M., Primeau, V., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/496986 · Cited by 995
Research works printed but not linked: 5
- Summary points on quarterly (October to December. 2008) and financial year (2007/08) acute Trust Clostridium difficile data. Key points: analyses of quarterly mandatory Clostridium difficile surveillance data. Health Protection Agency [online] , (2008).
- Thompson, A. et al. in Ninth Biennial Congress of the Anaerobe Society of Americas. PII-14 (Long Beach, California, 2008).
- Angulo, F. et al. in Second International Clostridium difficile Symposium. P5 (Maribor, Slovenia, 2007).
- Louie, T. et al. in The 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. K-425a (Chicago, Illinois, 2007).
- Merrigan, M. M., Gerding, D. N. & Vedantam, G. in Eighth Biennial Conference of the Anaerobe Society of America. PI-12 (Boise, Idaho, 2006).
Cited by
Items 401–500 of 999
Lantibiotics produced by Actinobacteria and their potential applications (a review)
Gomes, K. M., Duarte, R. S., & Bastos, M. D. C. D. F. (2016) · Microbiology · doi:10.1099/mic.0.000397 · Cited by 50
Antimicrobial effects of Manuka honey on in vitro biofilm formation by Clostridium difficile
Piotrowski, M., Karpiński, P., Pituch, H. M., van Belkum, A., & Obuch-Woszczatyński, P. (2017) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-017-2980-1 · Cited by 49
Preliminary studies on isolates of Clostridium difficile from dogs and exotic pets
Andrés-Lasheras, S., Martín‐Burriel, I., Jaime, R. C. M., Morales, M., Kuijper, E. J., Blanco, J. L., Chirino‐Trejo, M., & Bolea, R. (2018) · BMC Veterinary Research · doi:10.1186/s12917-018-1402-7 · Cited by 52
“difficile strains are the most common cause of antibiotic-associated diarrhoea in people from developed countries through the synthesis of toxins A and B, its main virulence factors [1].”
BackgroundBacteriophages Contribute to Shaping Clostridioides (Clostridium) difficile Species
Fortier, L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02033 · Cited by 52
“1 2006 • First C. difficile phage genome to be sequenced • The phage repressor RepR was shown to repress transcription of the five PaLoc genes through binding to the tcdR promoter element Govind et al., 2006, 2009 phiC2 M 56,538 DQ466086.”
InfluentialKachrimanidou, M., Tzika, E. D., & Filioussis, G. (2019) · Microorganisms · doi:10.3390/microorganisms7120667 · Cited by 53
“In cattle, PCR ribotype 078 has also been commonly detected in different European countries [12,26,61,140]Calves were mostly colonized already upon arrival to the farm and ribotypes 078 and 126 were persisting from the beginning to the last stages of the production cycle.”
BackgroundAthanase, K. K., Dadié, A., N’guessan, K. F., Djè, K. M., & Loukou, Y. G. (2014) · Anaerobe · doi:10.1016/j.anaerobe.2014.05.012 · Cited by 48
“difficile also appears to be an important cause of enteric disease in a variety of animal species, suggesting that animals and humans may share a common source [5].”
BackgroundOutcomes in patients tested for Clostridium difficile toxins
Polage, C. R., Chin, D. L., Leslie, J. L., Tang, J., Cohen, S. H., & Solnick, J. V. (2012) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2012.08.019 · Cited by 48
“Since then, the essential role of C. difficile toxins in CDI pathogenesis has been confirmed and a relationship between toxin concentration and severity has been observed (Kuehne et al. 2010; Akerlund et al. 2006; Lyras et al. 2009; Rupnik et al. 2009; Ryder et al. 2010).”
BackgroundPapatheodorou, P., Hornuß, D., Nölke, T., Hemmasi, S., Castonguay, J., Picchianti, M., & Aktories, K. (2013) · mBio · doi:10.1128/mbio.00244-13 · Cited by 48
“Clostridium difficile is a bacterial pathogen of the human intestine, leading to diarrhea and, in severe cases, to pseudomembranous colitis (1).”
BackgroundMatsuda, K., Tsuji, H., Asahara, T., Takahashi, T., Kubota, H., Nagata, S., Yamashiro, Y., & Nomoto, K. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.07990-11 · Cited by 50
“difficile and development of its infection have been described, including age, treatment with antibiotics, and hospital admission (40); those factors are considered to relate to changes in the intestinal microbiota, immunosenescence, or the presence of underlying diseases (44).”
BackgroundPizarro‐Guajardo, M., Calderón-Romero, P., & Paredes‐Sabja, D. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.01463-16 · Cited by 47
Pizarro‐Guajardo, M., Díaz-González, F., Álvarez-Lobos, M., & Paredes‐Sabja, D. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00365 · Cited by 49
“Given the natural resistance of C. difficile spores to antibiotics, they remain in dormant state and may germinate upon cease of antibiotic treatment, generating a new infection (Rupnik et al., 2009).”
BackgroundVeillonella intestinal colonization promotes C. difficile infection in Crohn’s disease
Yang, Z., Wang, J., Chen, Y., Chen, T., Shen, Z., Wang, Y., Jian, Y., Xiang, G., Ma, X., Zhao, N., et al. (2025) · Cell Host & Microbe · doi:10.1016/j.chom.2025.07.019 · Cited by 54
Khoruts, A., & Weingarden, A. R. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.07.016 · Cited by 47
Fang, Y., Chen, S.-Y., Huang, X., Wang, L., Wang, H.-Y., & Wang, J. (2013) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2013.09.063 · Cited by 47
Yakob, L., Riley, T. V., Paterson, D. L., & Clements, A. (2013) · BMC Infectious Diseases · doi:10.1186/1471-2334-13-376 · Cited by 58
“The infectious dose is small and the bacterium is capable of producing spores which can remain viable for years in the environment [24].”
BackgroundTakahashi, M., Mori, N., & Bito, S. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-005665 · Cited by 47
“Other risk factors include advanced age and proton pump inhibitor use.(10) 11 CDI Strengths and limitations of this study”
BackgroundBinding of Clostridium difficile toxins to human milk oligosaccharides
El-Hawiet, A., Kitova, E. N., Kitov, P. I., Eugenio, L., Ng, K. K.-S., Mulvey, G. L., Dingle, T. C., Szpacenko, A., Armstrong, G. D., & Klassen, J. S. (2011) · Glycobiology · doi:10.1093/glycob/cwr055 · Cited by 47
“…for translocating the toxins across the cell membrane; and (iii) a highly repetitive C-terminal region, which appears to be primarily responsible for 4 receptor binding (Dove et al. 1990; Voneichelstreiber et al. 1992; Voneichelstreiber et al. 1996; Rupnik et al. 2009; Pruitt et al. 2010).”
BackgroundGutelius, D., Hokeness, K. L., Logan, S. M., & Reid, C. W. (2013) · Microbiology · doi:10.1099/mic.0.072454-0 · Cited by 47
“It is a leading cause of nosocomial diarrhoea and pseudomembranous colitis worldwide (Carroll & Bartlett, 2011; Kelly & LaMont, 2008; Rupnik et al., 2009) with symptoms of C. difficile-associated disease (CDAD) ranging from mild diarrhoea to pseudomembranous colitis and potentially death.”
BackgroundSchmidt, D., Beamer, G., Tremblay, J. M., Steele, J. A., Kim, H. B., Wang, Y., Debatis, M., Sun, X., Kashentseva, E. A., Dmitriev, I. P., et al. (2016) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00730-15 · Cited by 52
“The emergence of antibiotic-resistant hypervirulent strains and the increase in disease relapse have complicated the treatment of CDI, leading to increases in hospital stay, morbidity, and mortality (1).”
BackgroundInfluentialCheng, J.-W., Xiao, M., Kudinha, T., Kong, F., Xu, Z.-P., Sun, L.-Y., Zhang, L., Fan, X., Xie, X.-L., & Xu, Y. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01621 · Cited by 47
“CDI is now considered a public health threat, with a dramatic rise in the incidence and severity of CDI observed in Europe and North America in the past two decades (Rupnik et al., 2009).”
Jain, S., Smyth, D., O’Hagan, B. M. G., Heap, J., McMullan, G., Minton, N. P., & Ternan, N. G. (2017) · Scientific Reports · doi:10.1038/s41598-017-17583-9 · Cited by 54
Probiotics for Prevention and Treatment of Clostridium difficile Infection
Valdés-Varela, L., Gueimonde, M., & Ruas‐Madiedo, P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-72799-8_10 · Cited by 60
Modeling the Role of the Microbiome in Evolution
Huitzil, S., Sandoval‐Motta, S., Frank, A., & Aldana, M. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.01836 · Cited by 49
Frentrup, M., Zhou, Z., Steglich, M., Meier‐Kolthoff, J. P., Göker, M., Riedel, T., Bunk, B., Spröer, C., Overmann, J., Blaschitz, M., et al. (2020) · Microbial Genomics · doi:10.1099/mgen.0.000410 · Cited by 47
“difficile over up to 25 years has been inferred previously on the basis of molecular epidemiology with lower resolution techniques [34].”
Hemmasi, S., Czulkies, B. A., Schorch, B., Veit, A., Aktories, K., & Papatheodorou, P. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.650523 · Cited by 46
Clostridium difficile Bacteremia, Taiwan1
Lee, N., Huang, Y., Hsueh, P., & Ko, W. (2010) · Emerging infectious diseases · doi:10.3201/eid1608.100064 · Cited by 48
Fry, P. R., Thakur, S., Abley, M. J., & Gebreyes, W. A. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.06581-11 · Cited by 50
“The common occurrence of toxinotype V in the present study underscores a potential concern, as this type has been associated with community-associated disease and increasing prevalence in CDI in humans (6, 21, 26, 27).”
BackgroundImmunization Using GroEL Decreases Clostridium difficile Intestinal Colonization
Péchiné, S., Hennequin, C., Boursier, C., Hoÿs, S., & Collignon, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0081112 · Cited by 54
“difficile colonizes the intestinal tract, resulting in a spectrum of disease from asymptomatic carriage to pseudomembranous colitis (PMC) [1,2,3].”
BackgroundInfluentialSpigaglia, P., Drigo, I., Barbanti, F., Mastrantonio, P., Bano, L., Bacchin, C., Puiatti, C., Tonon, E., Berto, G., & Agnoletti, F. (2014) · Anaerobe · doi:10.1016/j.anaerobe.2014.10.003 · Cited by 46
Bai, Y.-B., Wang, Y., Goulian, M., Driks, A., & Dmochowski, I. J. (2014) · Chemical Science · doi:10.1039/c4sc01190b · Cited by 46
Alonso, C. D., Dufresne, S. F., Hanna, D. B., Labbé, A., Treadway, S., Neofytos, D., Bélanger, S., Huff, C. A., Laverdière, M., & Marr, K. A. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.07.022 · Cited by 48
“Introduction Clostridium difficile is a Gram-positive bacterium responsible for > 500,000 cases of infectious diarrhea and > 14,000 deaths in the United States annually [1-4].”
BackgroundEsposito, G., Nobile, N., Gigli, S., Seguella, L., Pesce, M., D’Alessandro, A., Bruzzese, E., Capoccia, E., Steardo, L., Cuomo, R., et al. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00120 · Cited by 52
Toxigenic Clostridium difficile PCR ribotypes in edible marine bivalve molluscs in Italy
Troiano, T., Harmanus, C., Sanders, I. M. J. G., Pasquale, V., Dumontet, S., Capuano, F., Romano, V., & Kuijper, E. J. (2015) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2015.05.002 · Cited by 46
He, W., Yuan, Q., Zhang, Y.-B., Guo, M., Gong, A., Zhang, J., Wu, A., Huang, T., Qu, B., Li, H.-P., et al. (2016) · Toxins · doi:10.3390/toxins8100277 · Cited by 46
“It should be noted that some species from Clostridium genus, such as Clostridium difficile, are considered to be one of the significant causes of health care-associated infections [42], whereas other members from this genus may help in the treatment of diseases such as cancer, as those Clostridium can selectively targ…”
BackgroundAnalysis of Clostridium difficile biofilms: imaging and antimicrobial treatment
James, G. A., Chesnel, L., Boegli, L., Pulcini, E. D., Fisher, S. T., & Stewart, P. S. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx353 · Cited by 48
Péchiné, S., Bruxelle, J.-F., Janoir, C., & Collignon, A. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01009 · Cited by 51
“Clostridium difficile is involved in a wide spectrum of diseases from mild post-antibiotic diarrhea to pseudomembranous colitis (PMC) that can be severe and lead to complications such as toxic megacolon, septic shock, and death (Rupnik et al., 2009).”
BackgroundRstA Is a Major Regulator of Clostridioides difficile Toxin Production and Motility
Edwards, A. N., Anjuwon-Foster, B. R., & McBride, S. M. (2019) · mBio · doi:10.1128/mbio.01991-18 · Cited by 48
“Clinical outcomes range from mild diarrhea to severe disease symptoms, including sepsis and death (1).”
Duan, J., Meng, X., Liu, S., Zhou, P., Zeng, C., Fu, C., Dou, Q., Wu, A., & Li, C. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00190 · Cited by 46
Alam, Z. A., Wu, X., Mascio, C. T. M., Chesnel, L., & Hurdle, J. G. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01087-15 · Cited by 47
“The Gram-positive spore-forming anaerobic bacterium Clos-tridium difficile is the leading cause of hospital-acquired diarrhea in North America and Europe (1, 2).”
BackgroundZhang, Z., Chen, X., Hernandez, L. D., Lipari, P., Flattery, A. M., Chen, S.-C., Kramer, S., Polishook, J. D., Racine, F., Cape, H., et al. (2014) · Infection and Immunity · doi:10.1128/iai.02550-14 · Cited by 45
“In recent years, CDIassociated morbidity and mortality have increased significantly, and the disease poses a significant health care threat in the United States and globally (2).”
BackgroundPrevalence of Gastrointestinal Clostridium difficile Carriage in Australian Sheep and Lambs
Knight, D. R., & Riley, T. V. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01888-13 · Cited by 54
Berry, N., Sewell, B., Jafri, S., Puli, C., Vagia, S., Lewis, A. M., Davies, D., Rees, E., & Ch’ng, C. L. (2014) · Journal of Hospital Infection · doi:10.1016/j.jhin.2014.03.005 · Cited by 45
Protective Efficacy Induced by Recombinant Clostridium difficile Toxin Fragments
Leuzzi, R., Spencer, J., Buckley, A. M., Brettoni, C., Martinelli, M., Tulli, L., Marchi, S., Luzzi, E., Irvine, J. J., Candlish, D., et al. (2013) · Infection and Immunity · doi:10.1128/iai.01341-12 · Cited by 55
“Clostridium difficile is a Gram-positive, sporulating, toxigenic bacterium which colonizes and infects both humans and animals (1, 2).”
BackgroundDalpke, A. H., Hofko, M., Zorn, M., & Zimmermann, S. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.00344-13 · Cited by 45
Cheng, J., Xiao, M., Kudinha, T., Xu, Z., Sun, L., Hou, X., Zhang, L., Fan, X., Kong, F., & Xu, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144604 · Cited by 45
“difficile infection (CDI) is a major nosocomial disease, with clinical symptoms ranging from asymptomatic colonization, diarrhea to toxic megacolon, bowel perforation, sepsis, shock and death [1].”
BackgroundVariation in germination of Clostridium difficile clinical isolates correlates to disease severity
Carlson, P. E., Kaiser, A. M., McColm, S., Bauer, J. M., Young, V. B., Aronoff, D. M., & Hanna, P. C. (2015) · Anaerobe · doi:10.1016/j.anaerobe.2015.02.003 · Cited by 55
“The prevalence and severity of CDI have escalated over the last decade, with over a 250,000 cases resulting in 14,000 deaths occurring annually in the United States alone [1, 5, 6].”
BackgroundFecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead
Borody, T. J., Fischer, M., Mitchell, S., & Campbell, J. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1086267 · Cited by 47
“difficile strains in the community, meat, animals, soil and so on, reservoirs not traditionally associated with potential CDI infection [36].”
BackgroundJanssen, I., Cooper, P., Gunka, K., Rupnik, M., Wetzel, D., Zimmermann, O., & Groß, U. (2016) · International Journal of Medical Microbiology · doi:10.1016/j.ijmm.2016.09.004 · Cited by 44
Allegretti, J. R., Eysenbach, L. M., El‐Nachef, N., Fischer, M., Kelly, C. R., & Kassam, Z. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001247 · Cited by 48
Host Immune Responses to Clostridioides difficile: Toxins and Beyond
Nibbering, B., Gerding, D. N., Kuijper, E. J., Zwittink, R. D., & Smits, W. K. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.804949 · Cited by 63
Hargreaves, K. R., Colvin, H. V., Patel, K. V., Clokie, J. J. P., & Clokie, M. R. J. (2013) · Applied and Environmental Microbiology · doi:10.1128/aem.01849-13 · Cited by 58
“The disease is mediated by the production of up to three toxins, TcdA, TcdB, and the Clostridium difficile binary toxin (CDT) (3).”
BackgroundInfluentialClostridioides difficile Infection
Stewart, D. B. (2020) · Clinics in Colon and Rectal Surgery · doi:10.1055/s-0040-1701228 · Cited by 43
Clostridioides difficile Toxins: Host Cell Interactions and Their Role in Disease Pathogenesis
Alam, M. Z., & Madan, R. (2024) · Toxins · doi:10.3390/toxins16060241 · Cited by 42
“Multiple virulence factors are involved in the pathophysiology of CDI, but symptoms are mainly associated with the production of two exotoxins: toxin A and toxin B [9,20].”
BackgroundInfluentialVickers, R. J., Robinson, N., Best, E. L., ECHOLS, R. M., Tillotson, G., & Wilcox, M. H. (2015) · BMC Infectious Diseases · doi:10.1186/s12879-015-0759-5 · Cited by 46
“difficile to proliferate [1], with symptoms ranging from mild self-limiting diarrhoea to more serious manifestations including pseudomembranous colitis, toxic megacolon, bowel perforation, sepsis, and death [2].”
BackgroundClostridium difficile infection
Stanley, J. D., Bartlett, J. G., Dart, B. W., & Ashcraft, J. (2013) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2013.02.004 · Cited by 54
Anosova, N. G., Brown, A. M., Li, L., Liu, N., Cole, L. E., Zhang, J., Mehta, H., & Kleanthous, H. (2013) · Journal of Medical Microbiology · doi:10.1099/jmm.0.056796-0 · Cited by 46
“Clostridium difficile, a Gram-positive, spore-forming anaerobic bacillus, is a leading cause of nosocomial diarrhoea and pseudomembranous colitis worldwide (Rupnik et al., 2009).”
Hung, Y., Ko, W., Chou, P.-H., Chen, Y., Lin, H.-J., Liu, Y.-H., Tsai, H.-W., Lee, J., & Tsai, P.-J. (2015) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiv184 · Cited by 42
“United States, Canada, and Europe [3, 4].”
BackgroundHernandez, L. D., Kroh, H. K., Hsieh, E. J., Yang, X., Beaumont, M., Sheth, P. R., DiNunzio, E. N., Rutherford, S. A., Ohi, M. D., Ermakov, G., et al. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.02.010 · Cited by 42
“difficile infection (CDI) can cause mild symptoms such as a low-grade fever, watery stools, and minor abdominal cramping, as well as more severe symptoms such as bloody diarrhea, pseudomembrane colitis, toxic megacolon, and death [1].”
BackgroundLechner, S., Yee, M. F., Limketkai, B. N., & Pham, E. A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06100-0 · Cited by 44
Bratkovič, T., Zahirović, A., Bizjak, M., Rupnik, M., Štrukelj, B., & Berlec, A. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2337312 · Cited by 50
Collective dynamical regimes predict invasion success and impacts in microbial communities
Hu, J., Barbier, M., Bunin, G., & Gore, J. (2025) · Nature Ecology & Evolution · doi:10.1038/s41559-024-02618-y · Cited by 52
“Pathogenic microorganisms can invade host-associated microbial communities, leading to infections and disease 19,23,24 .”
The Ecology and Pathobiology of Clostridium difficile Infections: An Interdisciplinary Challenge
Dubberke, E. R., Haslam, D. B., Lanzas, C., Bobo, L. D., Burnham, C. D., Grohn, Y. T., & Tarr, P. I. (2010) · Zoonoses and Public Health · doi:10.1111/j.1863-2378.2010.01352.x · Cited by 46
“difficile binary toxin (CDT) (Rupnik et al., 2009).”
BackgroundInfluentialClostridium difficile infection in diabetes
Qu, H., & Jiang, Z. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.06.002 · Cited by 44
“In addition to antibiotic use, advanced age (>65 years old), impaired immune function, contact with CDI patients or their health care providers, and the use of acid-suppressive therapy, particularly proton pump inhibitors, are common factors increasing the risk of CDI [4–6].”
BackgroundCorbett, D. F., Wise, A., Birchall, S., Warn, P. A., Baines, S. D., Crowther, G. S., Freeman, J., Chilton, C. H., Vernon, J. J., Wilcox, M. H., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv006 · Cited by 45
Dannheim, H., Will, S. E., Schomburg, D., & Neumann‐Schaal, M. (2017) · FEBS Open Bio · doi:10.1002/2211-5463.12208 · Cited by 43
Gigli, S., Seguella, L., Pesce, M., Bruzzese, E., D’Alessandro, A., Cuomo, R., Steardo, L., Sarnelli, G., & Esposito, G. (2017) · United European Gastroenterology Journal · doi:10.1177/2050640617698622 · Cited by 44
“It is known that Clostridium difficile produces two enterotoxins, named Clostridium difficile toxin A and B (TcdA and TcdB, respectively) that, in turn, are responsible for the extensive colonic mucosal damage, causing severe diarrhoea, colitis, shock and death in most severe cases.(2,3) TcdA is the major cause of Clo…”
BackgroundSilver potentiates aminoglycoside toxicity by enhancing their uptake
Hérisse, M., Duverger, Y., Martin‐Verstraete, I., Barras, F., & Ezraty, B. (2017) · Molecular Microbiology · doi:10.1111/mmi.13687 · Cited by 42
“This is an important result as C. difficile infection is the most common cause of identifiable diarrhea in hospitalized adult patients and the incidence and severity of C. difficile infections increased (Rupnik et al., 2009; Lessa et al., 2015).”
BackgroundLiu, Y.-H., Chang, Y.-C., Chen, L.-K., Su, P.-A., Ko, W., Tsai, Y.-S., Chen, Y., Lai, H., Wu, C.-Y., Hung, Y., et al. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00084 · Cited by 47
“To date, significantly expanding incidences and morbidity rates related to CDI have been reported since the 1980s and have been largely attributed to the presence of new hypervirulent strains called NAP1/BI/027, which have been implicated as the cause of numerous epidemics in the United States, Canada, Europe, and Asi…”
BackgroundInfluentialDong, D., Ni, Q., Wang, C., Zhang, L., Li, Z., Jiang, C., EnqiangMao, & Peng, Y. (2018) · BMC Infectious Diseases · doi:10.1186/s12879-018-3111-z · Cited by 42
“difficile infection has dramatically increased over past decades [3].”
BackgroundAlonso, C. D., & Mahoney, M. V. G. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s159957 · Cited by 48
“Toxins A and B belong to a class of Clostridial toxins that cause colonic tissue damage to the enteric cytoskeletal wall and disruption of the tight junctions that connect colonic cells.(10) Changes to the cell wall combined with secretion of inflammatory mediators result in recruitment of neutrophils to the site of i…”
BackgroundAkha, A. A. S., Theriot, C. M., Erb‐Downward, J. R., McDermott, A. J., Falkowski, N. R., Tyra, H. M., Rutkowski, D. T., Young, V. B., & Huffnagle, G. B. (2013) · Immunology · doi:10.1111/imm.12122 · Cited by 47
Predictors of fecal transplant failure
Meighani, A., Hart, B. R., Mittal, C., Miller, N., John, A., & Ramesh, M. (2016) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000614 · Cited by 39
Molodtsov, V., Fleming, P. R., Eyermann, C. J., Ferguson, A. D., Foulk, M. A., McKinney, D. C., Masse, C. E., Buurman, E. T., & Murakami, K. S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00050 · Cited by 46
The microbiota and immune response during Clostridium difficile infection
Buonomo, E. L., & Petri, W. A. (2016) · Anaerobe · doi:10.1016/j.anaerobe.2016.05.009 · Cited by 55
Vaginal dysbiotic bacteria act as pathobionts of the protozoal pathogen Trichomonas vaginalis
Hinderfeld, A. S., & Simões-Barbosa, A. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103820 · Cited by 41
Ageing, immunity and influenza: a role for probiotics?
Yaqoob, P. (2014) · Proceedings of the Nutrition Society · doi:10.1017/s0029665113003777 · Cited by 40
“Reduced biodiversity may result in increased colonisation of toxin-producing Clostridium difficile, a major nosocomial complication affecting older people((8,9)).”
Kawada, M., Masuda, Y., Inamatsu, T., ANNAKA, M., Shibasaki, S., Hikosaka, K., Mizuno, H., Inamatsu, T., Kato, H., & Kawada, M. (2011) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-011-0267-5 · Cited by 39
“To make an accurate and efficient diagnosis of CDI, researchers have proposed testing algorithms, such as one that consists of an initial screening by EIA-based GDH detection, a rapid toxin detection test for GDH-positive specimens, and a final confirmatory test for GDH-positive/ toxin-negative specimens by a cytotoxi…”
MethodMolecular Basis of Early Stages of Clostridium difficile Infection: Germination and Colonization
Sarker, M. R., & Paredes‐Sabja, D. (2012) · Future Microbiology · doi:10.2217/fmb.12.64 · Cited by 49
Infecciones producidas por Clostridium difficile
Rodríguez-Pardo, D., Mirelis, B., & Navarro, F. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2012.12.010 · Cited by 39
A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors
Larocque, M., Chénard, T., & Najmanovich, R. (2014) · BMC Systems Biology · doi:10.1186/s12918-014-0117-z · Cited by 47
“These toxins are responsible for the clinical symptoms of C. difficile infection (CDI) (Voth & Ballard, 2005; Rupnik et al , 2009).”
BackgroundIn vitro inhibition of Clostridium difficile by commercial probiotics: A microcalorimetric study
Fredua‐Agyeman, M., Stapleton, P. D., Basit, A. W., Beezer, A. E., & Gaisford, S. (2016) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2016.12.005 · Cited by 42
“When germinated, the spores produce enterotoxin (Toxin A), and cytotoxin (Toxin B) which mediate severe inflammatory response and epithelial damage resulting in the main clinical symptoms and signs of C. difficile infection: secretory diarrhoea and pseudomembranous colitis (Rupnik et al., 2009).”
BackgroundPiotrowski, M., Wultańska, D., Obuch-Woszczatyński, P., & Pituch, H. M. (2019) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-019-03635-7 · Cited by 39
Kunishima, H., Ohge, H., Suzuki, H., Nakamura, A., Matsumoto, K., Mikamo, H., Mori, N., Morinaga, Y., Yanagihara, K., Yamagishi, Y., et al. (2022) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2021.12.011 · Cited by 48
Stoesser, N. E., Crook, D. W., Fung, R., Griffiths, D., Harding, R. M., Kachrimanidou, M., Keshav, S., Peto, T., Vaughan, A., Walker, A. S., et al. (2011) · Journal of Clinical Microbiology · doi:10.1128/jcm.05349-11 · Cited by 39
“The symptoms of Clostridium difficile-associated infection (CDI) are attributed to the production of toxin A and/or toxin B encoded by the genes tcdA and tcdB within the pathogenicity locus (PaLoc) (15).”
BackgroundRole of Clinicogenomics in Infectious Disease Diagnostics and Public Health Microbiology
Westblade, L. F., van Belkum, A., Grundhoff, A. T., Weinstock, G. M., Pamer, E. G., Pallen, M. J., & Dunne, W. M. (2016) · Journal of Clinical Microbiology · doi:10.1128/jcm.02664-15 · Cited by 40
“difficile infection (33, 36), which is a major cause of infectious diarrhea in hospitalized patients (37).”
BackgroundPathogenesis of Clostridium difficile Infection and Its Potential Role in Inflammatory Bowel Disease
Monaghan, T. M., Cockayne, A., & Mahida, Y. R. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000461 · Cited by 38
“difficile isolates, the PaLoc is absent and is replaced by a 115 bp sequence.(19) At least 4 functionally distinct domains of toxins A and B have been identified and include, from the N-terminal region, enzy-”
BackgroundClostridium difficile infection in patients with liver disease: a review
Trifan, A. V., Stoica, O. C., Stanciu, C., Cojocariu, C., Sîngeap, A.-M., Gîrleanu, I., & Miftode, E. G. (2015) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-015-2501-z · Cited by 39
“After binding to receptors on the enterocyte, the toxin penetrates the cell through receptor-mediated endocytosis, followed by glycosylation of Rho and Ras proteins, leading to disruption of the epithelial cytoskeleton, and, subsequently, to inflammatory diarrhea [67].”
BackgroundSurvival of Clostridium difficile spores at low temperatures
Deng, K., Plaza-Garrido, Á., Torres, J. A., & Paredes‐Sabja, D. (2014) · Food Microbiology · doi:10.1016/j.fm.2014.07.022 · Cited by 44
“Most episodes of C. difficile infections 41 (CDI) are believed to be acquired from healthcare settings through person-to-person transmission 42 or from the hospital environment (Rupnik et al., 2009).”
The membrane as a target for controlling hypervirulent Clostridium difficile infections
Wu, X., Cherian, P., Lee, R. E., Jr., & Hurdle, J. G. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks493 · Cited by 43
The multidomain flavodiiron protein from Clostridium difficile 630 is an NADH:oxygen oxidoreductase
Folgosa, F., Martins, M. C., & Teixeira, M. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-28453-3 · Cited by 42
Appaneal, H. J., Caffrey, A. R., & LaPlante, K. L. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy1077 · Cited by 41
“A priori, we chose to study 30-day CDI recurrence from the end of therapy, because most cases of CDI recur within 1-3 weeks after treatment.[10, 29, 37-39] Moreover, a consensus definition for CDI recurrence has not been established and most previous CDI clinical trials have assessed outcomes at 28-30 days post-treatm…”
MethodFrisbee, A. L., & Petri, W. A. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.01.009 · Cited by 46
“difficile diarrheal disease through the killing of colonic host-epithelial cells and breakdown of the gut barrier[14].”
Lysozyme Resistance in Clostridioides difficile Is Dependent on Two Peptidoglycan Deacetylases
Kaus, G. M., Snyder, L. F., Müh, U., Flores, M. J., Popham, D. L., & Ellermeier, C. D. (2020) · Journal of Bacteriology · doi:10.1128/jb.00421-20 · Cited by 38
“difficile infections are the most common cause of hospital-acquired diarrhea worldwide, with disease severity ranging from mild diarrhea to severe cases of pseudomembranous colitis (1, 2).”
BackgroundHussack, G., & Tanha, J. (2010) · Toxins · doi:10.3390/toxins2050998 · Cited by 38
“difficile-associated disease (CDAD) [1–3].”
Colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection in a child
Kahn, S. A., Young, S., & Rubin, D. T. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.351 · Cited by 37
The Spore Coat Protein CotE Facilitates Host Colonization by Clostridium difficile
Hong, H. A., Ferreira, W. T., Hosseini, S., Anwar, S., Hitri, K., Wilkinson, A. J., Vahjen, W., Zentek, J., Soloviev, M., & Cutting, S. M. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix488 · Cited by 39
“Another possibility is that the severity of disease is due to the combined action of toxins and spores interacting with the large number of macrophages and neutrophils produced during the acute stages of infection leading to the production of inflammatory cytokines [3].”
BackgroundYan, L., Roux, A. L., Boyapelly, K., Lamontagne, A.-M., Archambault, M.-A., Picard‐Jean, F., Séguin, D. L., St-Pierre, É., Najmanovich, R., Fortier, L., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.079 · Cited by 36
Proteomic Comparison of Historic and Recently Emerged Hypervirulent Clostridium difficile Strains
Chen, J., Scaria, J., Mao, C., Sobral, B., Zhang, S., Lawley, T. D., & Chang, Y.-F. (2013) · Journal of Proteome Research · doi:10.1021/pr3007528 · Cited by 36
The LexA regulated genes of the Clostridium difficile
Walter, B. M., Rupnik, M., Hodnik, V., Anderluh, G., Dupuy, B., Paulič, N., Žgur‐Bertok, D., & Butala, M. (2014) · BMC Microbiology · doi:10.1186/1471-2180-14-88 · Cited by 45
“difficile is a human pathogen causing a spectrum of intestinal diseases ranging from mild diarrhoea associated with antibiotic treatment to, in more severe cases, pseudomembraneous colitis [13].”
BackgroundHuang, B., Jin, D., Zhang, J., Sun, J. Y., Wang, X., Stiles, J., Xu, X., Kamboj, M., Babady, N. E., & Tang, Y. (2014) · Journal of Clinical Microbiology · doi:10.1128/jcm.02601-13 · Cited by 36
Metadata
- Authors
- Rupnik, M., Wilcox, M. H., & Gerding, D. N.
- Affiliations
- University of Maribor (SI)
- Leeds General Infirmary (GB)
- Loyola University Chicago (US)
- Venue
- Nature Reviews Microbiology
- Published
- 2009-07
- Volume
- 7
- Issue
- 7
- Pages
- 526-536
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1968953113
- Cited by
- 1,380
- References
- 124
- Citations by year
- 2026: 18 · 2025: 36 · 2024: 49 · 2023: 59 · 2022: 74 · 2021: 72 · 2020: 88 · 2019: 78 · 2018: 109 · 2017: 104 · 2016: 107 · 2015: 107 · 2014: 133 · 2013: 141 · 2012: 93
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Keywords
- Clostridium difficile infection, nosocomial infections, virulence factors, epidemiology, pathogenesis, community-acquired infections, food-producing animals, antibiotic-associated diarrhea, clinical outcomes, infection prevention and treatment
- MeSH terms
- Animals, Anti-Bacterial Agents, Enterocolitis, Pseudomembranous, Humans, Models, Theoretical, Clostridioides difficile, Virulence Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.